<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00863837</url>
  </required_header>
  <id_info>
    <org_study_id>NSC</org_study_id>
    <nct_id>NCT00863837</nct_id>
  </id_info>
  <brief_title>Prevention of Esophageal Variceal Rebleeding</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Science Council, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Previous studies showed that the combination of endoscopic therapy with&#xD;
      vasoconstrictor is better than either vasoconstrictor or endoscopic therapy alone in&#xD;
      achieving the successful hemostatsis of acute variceal bleeding. The rationale of using&#xD;
      vasoconstrictor is to enhance the efficacy of hemostasis by endoscopic therapy. Nowadays,&#xD;
      endoscopic variceal ligation (EVL) has replaced endoscopic injection sclerotherapy (EIS) as&#xD;
      the endoscopic treatment of choice in the arresting of acute esophageal variceal hemorrhage.&#xD;
      EVL alone can achieve hemotasis up to 97% even in cases of active variceal hemorrhage.&#xD;
      However, early rebleeding due to ligation-induced ulcer may be encountered. It appears that&#xD;
      prevention of esophageal ulcers and bleeding by a proton pump inhibitor may be more logical&#xD;
      than using a vasoconstrictor after cessation of bleeding by EVL.&#xD;
&#xD;
      Thus, the investigators designed a controlled trial to compare the initial hemostasis, early&#xD;
      rebleeding rate in cirrhotic patients presenting with acute variceal bleeding receiving&#xD;
      either emergency EVL plus vasoconstrictor infusion or losec infusion for 5 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods of treatment:&#xD;
&#xD;
      Group 1: Somatostatin 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours)&#xD;
      or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5&#xD;
      days. The use of either somatostatin or glypressin was at the discretion of doctors in&#xD;
      charge. Group 2: Pantoloc 20 mg intravenously per day was instituted on enrollment and&#xD;
      continued for 5 days.&#xD;
&#xD;
      Definition of initial hemostasis:&#xD;
&#xD;
      Initial hemostasis was defined as achieving a 24h bleeding-free period within the first 48h&#xD;
      after treatment together with stable vital signs based on Baveno consensus criteria.&#xD;
&#xD;
      Very early rebleeding was defined as: UGI bleeding occurred after initial hemostasis and&#xD;
      within 5 days after enrollment. UGI bleeding was proven to be from esophageal varices.&#xD;
&#xD;
      Treatment failure is defined as failure to control acute bleeding episodes or very early&#xD;
      rebleeding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>December 2006</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>very early rebleeding</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality, complications</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Esophageal Variceal Rebleeding</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>add pantoloc to reduce ulcer bleeding after banding ligation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: ligation + terlipressin 1mg q6h</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm B, intervention: ligation + terlipressin 1mg q6h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terlipressin (vasoconstrictor)</intervention_name>
    <description>Ligation plus terlipressin 1mg q6h</description>
    <arm_group_label>Arm B: ligation + terlipressin 1mg q6h</arm_group_label>
    <other_name>vasoconstrictor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pantoloc (proton pump inhibitor)</intervention_name>
    <description>Pantoloc infusion (1 vial q.d.); Using pantoloc to reduce rebleed after EVL</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>proton pump inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The etiology of portal hypertension is cirrhosis.&#xD;
&#xD;
          2. Age ranges between 18-80 y/o.&#xD;
&#xD;
          3. Patients presenting with acute esophageal variceal bleeding proven by emergency&#xD;
             endoscopy within 12 hours. (Acute esophageal variceal bleeding was defined as:&#xD;
&#xD;
               -  when blood was directly seen by endoscopy to issue from an esophageal varix&#xD;
                  (active bleeding) OR&#xD;
&#xD;
               -  when patients presented with red color signs on their esophageal varices with&#xD;
                  blood in esophagus or stomach and no other potential site of bleeding identified&#xD;
                  (inactive bleeding).&#xD;
&#xD;
          4. EVL is performed after confirmation of acute esophageal variceal bleeding. Enrollment&#xD;
             time: Immediately after EVL is completed and variceal bleeding is arrested.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. association with severe systemic illness, such as sepsis, COPD, uremia&#xD;
&#xD;
          2. association with gastric variceal bleeding&#xD;
&#xD;
          3. failure in the control of bleeding by emergency EVL&#xD;
&#xD;
          4. moribund patients, died within 12 hours of enrollment&#xD;
&#xD;
          5. Uncooperative&#xD;
&#xD;
          6. Ever received EIS, EVL within one month prior to index bleeding&#xD;
&#xD;
          7. Child-Pugh's scores &gt; 10&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 16, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <last_update_submitted>March 17, 2009</last_update_submitted>
  <last_update_submitted_qc>March 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gin-Ho Lo</name_title>
    <organization>Kaohsiung Veterans General Hospital</organization>
  </responsible_party>
  <keyword>Acute variceal bleeding</keyword>
  <keyword>banding ligation</keyword>
  <keyword>vasoconstrictor</keyword>
  <keyword>proton pump inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

